· Published by Health Canada · Official notice
This is duplicated text of a letter from Hoffmann-La Roche Limited.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
July 30, 2004
Subject: Possible association between RITUXAN and the recurrence of hepatitis B
Hoffmann-La Roche Limited, in consultation with Health Canada, has informed Canadian healthcare professionals of important new safety information concerning RITUXAN (rituximab). This drug is used to treat some types of lymphomas (cancers of the lymph nodes) either alone or with chemotherapy. Please note the following new safety information for the use of RITUXAN:
Hoffmann-La Roche Limited has continued to gather information on the safety and efficacy of RITUXAN since RITUXAN was introduced to the market.
If hepatitis B infection re-occurs, RITUXAN and any associated chemotherapy should be discontinued and appropriate treatment should be prescribed.
Signs and symptoms of hepatitis B include:
Patients who experience any of these symptoms should contact their physician immediately.
This advisory is in addition to a letter issued to healthcare professionals discussing the above-mentioned safety information. This letter can be accessed at Health Canada's web site at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2004/index-eng.php
The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of healthcare professionals in adverse reaction reporting programmes. Any recurrences of hepatitis B virus infection or other serious and/or unexpected adverse reactions in patients receiving RITUXAN should be reported to Hoffmann-La Roche Limited or Health Canada at the following addresses:
Hoffmann-La Roche Limited
Drug Information and Safety Department
2455 Meadowpine Boulevard
Mississauga, ON L5N 6L7
or call toll-free at 1-888-762-4388
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
For other inquiries: please refer to contact information.
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
original signed by
Lorenzo Biondi
Vice President,
Medical and Regulatory Affairs